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Organ transplant recipients (OTRs) have a 100- fold increased risk of cutaneous squa-
mous cell carcinoma (cSCC). We prospectively evaluated the association between β 
genus human papillomaviruses (βPV) and keratinocyte carcinoma in OTRs. Two OTR 
cohorts without cSCC were assembled: cohort 1 was transplanted in 2003- 2006 (n 
= 274) and cohort 2 was transplanted in 1986- 2002 (n = 352). Participants were 
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1  | INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC) is the most common ma-
lignancy in solid organ transplant recipients (OTRs), followed by basal 
cell carcinoma (BCC).1,2 The incidence of cSCC and BCC increases with 
duration of immunosuppressive therapy.1 Important risk factors are 
male sex, increasing age, fair skin type, sun exposure, and smoking.3 
cSCCs are usually preceded by multiple viral warts from human pap-
illomavirus (HPV) infection and by actinic keratoses, which also often 
contain HPV.3
The virome component of the human microbiome is known to 
play an important role in disease,4,5 and HPV is particularly prevalent 
in the normal skin virome.6,7 HPVs are double- stranded DNA viruses 
that are classified into 5 genera (α, β, γ, μ, and ν).8,9 αHPVs (eg, mu-
cosal HPV types 16 and 18) are responsible for the development of 
cervical carcinoma and other mucosal SCCs, including anogenital and 
oropharyngeal carcinomas.10 The role of skin βPVs in cSCC carcino-
genesis is controversial,9,11,12 but evidence for etiologic involvement 
is accumulating.13-17 βPV cause latent, persistent skin infections18 and 
were first discovered in cSCCs from patients with epidermodysplasia 
verruciformis, a rare genetic skin disease characterized by increased 
susceptibility to βPV with a high risk of cSCC on sun- exposed skin.9
βPVs are ubiquitous, with more than 90% of people carrying these 
viruses as part of their normal skin virome.7,19,20 Hair follicles are the 
likely reservoir.18 βPV- infected cells may have impaired DNA repair 
and decreased sensitivity to apoptosis induced by ultraviolet radiation 
(UVR), facilitating escape from normal cellular defense mechanisms.9,13 
A substantial body of epidemiologic data show an association between 
HPV infection and cSCC,12,20-24 in particular, in OTRs.25,26 In most 
studies, HPV infection has been determined by detection of serologic 
responses to a large series of βPV and sometimes γPV types12,21–23,25–31 
and less frequently by detecting genomic DNA from 1 or multiple HPV 
types in eyebrow hair or skin scrapings.20,21,25,32-34
Case- control studies in both OTR and immunocompetent popu-
lations have shown that the presence of βPV DNA or antibodies was 
associated with a 1.5- to 3- fold increased risk of cSCC.12,20–26,29,31,32 
It was not possible, however, to determine whether the βPV infection 
increases risk of cSCC development or whether cSCC formation pro-
motes active proliferation of βPV. To our best knowledge, there is only 
1 published cohort study in OTRs that investigated the influence of 
βPV infection on the development of cSCC.26 In a single- center study 
in 445 patients, OTRs who were βPV seropositive around the time 
of transplantation had an almost 3- fold increased risk of developing 
cSCC during the 22- year follow- up period.26 There are no prospective 
studies in which the associations between cSCC and both the number 
and DNA load of βPV types have been examined.
In this study, we present data from 2 prospective multicenter co-
hort studies confirming that the presence of human skin βPV infection 
is associated with cSCC development in OTRs.
2  | METHODS
2.1 | Participants and study design
As part of a European Union–funded fifth framework program 
(5FP) collaborative research grant (QLK2- CT- 2002- 0117), the EPI- 
HPV- UV- CA study group collected data for a prospective35 and a 
case- control study between 2003 and 2006.3,25 A description of 
the inclusion and exclusion criteria is provided in the supplementary 
material (Figures S1A- S1C). Cohort 1 was assembled from 441 OTRs 
followed until death or cessation of follow- up in 2016. βPV infection was assessed in 
eyebrow hair by using polymerase chain reaction–based methods. βPV IgG serore-
sponses were determined with multiplex serology. A competing risk model with de-
layed entry was used to estimate cumulative incidence of histologically proven cSCC 
and the effect of βPV by using a multivariable Cox regression model. Results are re-
ported as adjusted hazard ratios (HRs). OTRs with 5 or more different βPV types in 
eyebrow hair had 1.7 times the risk of cSCC vs OTRs with 0 to 4 different types (HR 
1.7, 95% confidence interval 1.1- 2.6). A similar risk was seen with high βPV loads (HR 
1.8, 95% confidence interval 1.2- 2.8). No significant associations were seen between 
serum antibodies and cSCC or between βPV and basal cell carcinoma. The diversity and 
load of βPV types in eyebrow hair are associated with cSCC risk in OTRs, providing evi-
dence that βPV is associated with cSCC carcinogenesis and may present a target for 
future preventive strategies.
K E Y W O R D S
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who participated in the prospective study.35 Of these, 167 were ex-
cluded due to lack of sufficient follow- up data, leaving a final cohort of 
274 OTRs. Cohort 2 was established from 915 OTRs who participated 
in the case- control study.3,25 Exclusion of OTRs with lack of sufficient 
follow- up data (n = 242), an cSCC diagnosed before recruitment (n 
= 210), or transplanted before 1986 (n = 111) gave a total of 352 
OTRs. Both cohorts were under prospective observation until 2016.
Between 2003 and 2006, relevant demographic data and infor-
mation about skin cancer risk factors were collected.3,25,35 Plucked 
eyebrow hair was collected; DNA was extracted for detection and 
genotyping of 25 βPV types using the skin βPV prototype research 
assay (Labo Bio- medical Products BV, Rijswijk, The Netherlands)36 and 
for viral load determination using quantitative polymerase chain re-
action.32 Because more than 95% of OTRs had 1 or more βPV types 
in their eyebrow hair,25 we dichotomized the number of βPV as 0 to 
4 and as 5 or more, as previously published.25 High viral load was de-
fined as 1 βPV copy per 1 to 19 cells and low load as 1 copy per 20 or 
more cells. Serum was collected and tested for 16 βPV, 6 γPV, 4 αPV, 
2 μPV, and 1 νPV IgG antibodies with a multiplex serology technique 
based on glutathione s- transferase capture ELISA in combination with 
fluorescent bead technology.37,38 All 3 techniques used have been 
previously described in more detail.25,32,35-38
In cohort 1, eyebrow hair and serum were collected at 1, 3, 6, 9, 
12, and 18 months posttransplantation. The 12- month posttransplan-
tation time point was selected for the final analyses, because this time 
point best represented the βPV DNA measurement, as separate anal-
yses have shown (Figures S2A and S2B). No participants had devel-
oped cSCC before this time point. In cohort 2, DNA and serum were 
collected at the time of recruitment, a median of 10 (range 2- 19) years 
after transplantation. This was assumed to be representative of βPV 
DNA status in the years before sampling as βPV infection is character-
ized by a chronic persistent course with βPV DNA content in eyebrow 
hair being stable over time.18
All OTRs were routinely seen 1 to 4 times per year in specialized 
centers dedicated to surveillance of OTRs with skin lesions. Clinical 
information was collected from the time of enrolment between 2003 
and 2006 until the last follow- up in 2016 and included the first histo-
logically confirmed cSCC and BCC and the date of the last follow- up 
or death. We used medical charts, local pathology records, and local 
oncology databases to collect this information. Both cohort studies 
adhered to the Declaration of Helsinki principles, and the local medical 
ethical committees of the hospitals in the participating countries had 
approved the study design.
2.2 | Statistical analysis
Cohorts 1 and 2 were analyzed separately and in combination. To 
estimate the independent effect of risk factors on the occurrence of 
cSCC or BCC, a Cox model was used. Second and subsequent cSCCs 
or BCCs were not considered, because these data were not collected. 
The starting date for analysis was the day of transplantation; the end 
dates for those not diagnosed with cSCC or BCC were the end of 
follow- up or death. Proportionality of the hazard was assessed by 
plotting Schoenfeld residuals for relevant covariates and by introduc-
ing interactions of relevant covariates with time in the Cox model. A 
value of P < .05 indicated a violation of the proportionality assumption.
A competing risk model with death as competing event and de-
layed entry (also referred to as left truncation) was used to estimate 
the cumulative incidence of first cSCC or BCC since transplanta-
tion.39,40 Competing risk models take into account situations where 
more than 1 cause of failure is possible. In our study, the 2 competing 
events were cSCC or BCC and death, as patients might have died be-
forethe occurrence of cSCC or BCC. Delayed entry was used to adjust 
for the fact that in cohort 2 the HPV DNA testing and serology were 
not performed at the time of transplantation and that we had taken 
the 12- month time point in cohort 1.
We had previously defined a new variable based on concordance 
of βPV DNA and serology. We classified OTR according to whether 
they were both antibody and DNA positive for the same βPV type as 
follows: antibody negative, regardless of DNA status; antibody posi-
tive but with no types for which DNA was also found; and antibody 
positive with at least 1 type concordant for DNA.25
The final analyses were adjusted for sex, age, skin type, and study 
center (study center being an important composite variable represent-
ing differences in patient populations, immunosuppression regimens, 
and sun exposure between the 3 clinical sites). We also investigated 
the other clinical variables, and none changed the estimates of inter-
est. These were, therefore, not included in the analysis. Analyses of 
cohort 2 or of the combined cohorts showed that adjustment for type 
of immunosuppression, type of organ transplanted, average sun expo-
sure, number of sunburns, smoking, or alcohol consumption did not 
substantially change the hazard ratios (HRs) (data not shown). We did 
not adjust for keratotic skin lesions and common viral warts, as these 
potentially lie on the causal pathway between HPV infection and cSCC 
or BCC and their inclusion in the model may lead to overadjustment, 
biasing the result toward the null.41
The analyses concerning the competing risk model were per-
formed in R environment (http://www.R-project.org) with the mstate 
library.42 All other analyses were performed with SPSS Statistics for 
Windows version 23.0 (IBM Corp., Armonk, NY).
3  | RESULTS
The median and maximum follow- up times since transplantation were 
9.5 and 12.4 years in cohort 1 and 18.7 and 29.9 years in cohort 2, 
respectively. The median and maximum follow- up times since DNA 
and serum sampling did not differ between the cohorts and were 9.8 
and 13.4 years, respectively. At the end of follow- up, 161 (26%) of 
626 OTRs had died: 52 (19%) of 274 OTRs in cohort 1 and 109 (31%) 
of 352 OTRs in cohort 2.
The clinical profile of transplanted patients differed between co-
horts 1 and 2 (Table 1), but there were no significant differences in vi-
rologic results and association with cSCC. OTRs in cohort 1 were more 
often female, had a darker skin type, were less often smokers, and 
had lower alcohol consumption. Almost all received mycophenolate 
     |  1223BOUWES BAVINCK Et Al.
TABLE  1 Baseline characteristics of the 626 organ transplant recipients
Cohort 1 Cohort 2 Combined cohort
No. of patients 274 352 626
Years of first transplantation 2003- 2006 1986- 2002 1986- 2006
Study center, n (%)
Leiden (The Netherlands) 101 (36.9) 91 (25.9) 192 (30.7)
Lyon (France) 99 (36.1) 64 (18.2) 163 (26.0)
London (UK) 32 (11.7) 123 (34.9) 155 (24.8)
Bergamo (Italy) 42 (15.3) 74 (21.0) 116 (18.5)
P < .001
Sex, n (%)
Women 98 (35.8) 96 (27.3) 194 (31.0)
Men 176 (64.2) 256 (72.7) 432 (69.0)
P = .023
Age at transplantation, y
Median 56.4 50.3 52.4
IQR (25%- 75%) 47.9- 62.6 38.4- 57.3 42.0- 58.9
P = .003
Age at physical examination, y
Median 56.4 59.8 58.2
IQR (25%- 75%) 48.0- 62.6 52.7- 67.1 51.3- 65.7
P < .001
Skin phototype, n (%)
Dark/olive 157 (57.5) 162 (46.0) 319 (51.1)
Medium 91 (33.3) 128 (36.4) 219 (35.0)
Fair 25 (9.2) 62 (17.6) 87 (13.9)
Missing values (1) P = .002
Type of organ, n (%)
Kidney 220 (80.3) 288 (81.9) 508 (81.2)
Kidney and pancreas 34 (12.4) 29 (8.2) 63 (10.0)
Heart 20 (7.3) 35 (9.9) 55 (8.8)
P = .140
Immunosuppressive therapy, n (%)
Aza in any combination 14 (5.1) 148 (42.0) 162 (25.9)
MMF in any combination 251 (92.0) 108 (30.7) 359 (57.5)
CyA or Tac without Aza or MMF 8 (2.9) 96 (27.3) 104 (16.6)
Missing values (1) P < .001
Average daily sun exposure, n (%)
1- 3 h 175 (63.9) 208 (59.1) 383 (61.2)
≥4 h 99 (36.1) 144 (40.9) 243 (38.8)
P = .224
Sunburns before the age of 20 y, n (%)
0 110 (40.4) 174 (49.4) 284 (45.5)
1- 4 108 (39.7) 123 (34.9) 231 (37.0)
≥5 54 (19.9) 55 (15.6) 109 (17.5)
Missing values (2) P = .073
(Continues)
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mofetil in combination with tacrolimus, rather than azathioprine, 
which was the main immunosuppressive drug in cohort 2. The num-
bers of keratotic lesions and common viral warts were higher in co-
hort 2, consistent with their longer duration of immunosuppression 
(Table 1).
Table 2 shows the cause- specific HRs for prognostic factors as-
sociated with cSCC in the 2 cohorts combined. Results generated 
from individual cohort analyses are comparable (Tables S1 and S2). 
Male sex, increasing age, fair skin type, and immunosuppression with 
azathioprine were the strongest risk factors for cSCC. Because the 
Cohort 1 Cohort 2 Combined cohort
Smoking, n (%)
No 139 (50.8) 133 (38.1) 272 (43.7)
1- 19 pack- y 76 (27.7) 136 (39.0) 212 (34.0)
≥20 pack- y 59 (21.5) 80 (22.9) 139 (22.3)
Missing values (3) P = .003
Alcohol consumption, n (%)
No 112 (57.1) 98 (27.8) 210 (38.3)
1- 19 g/d 64 (32.7) 188 (53.4) 252 (56.0)
≥20 g/d 20 (10.2) 66 (18.8) 86 (15.7)
Missing values (78) P < .001
Keratotic skin lesions, n (%)
0 205 (74.8) 111 (31.6) 316 (50.6)
1- 49 65 (23.7) 208 (59.3) 273 (43.6)
≥50 4 (1.5) 32 (9.1) 36 (5.8)
Missing values (1) P < .001
Common viral warts, n (%)
0 234 (85.7) 203 (57.8) 437 (70.0)
1- 49 33 (12.1) 103 (29.3) 136 (21.8)
≥50 6 (2.2) 45 (12.8) 51 (8.2)
Missing values (1) (1) P < .001
No. of βPV types in hair
Median 4.5 4.0 4.0
IQR (25%- 75%) 2.3- 6.8 2.0- 8.0 2.0- 7.0
P = .643
No. of βPV types in hair
0- 4 142 (51.8) 174 (49.4) 316 (50.5)
≥5 132 (48.2) 178 (50.6) 310 (49.5)
P = .552
βPV load (based on 8 βPV types)
Low load (1 copy per ≥20 cells) 195 (71.2) 252 (71.6) 447 (71.4)
High load (1 copy per <20 cells) 79 (28.8) 100 (28.4) 179 (28.6)
P = .907
HPV seropositivity
αPV 165 (60.2) 188 (53.4) 353 (56.4)
βPV 137 (50.0) 176 (50.0) 313 (50.0)
γPV 133 (48.5) 165 (46.9) 298 (47.6)
μPV 91 (33.2) 100 (28.4) 192 (30.5)
νPV 31 (11.3) 31 (8.8) 62 (9.9)
P > .05
The P- values refer to the differences between cohorts 1 and 2 and are calculated with a χ2 test (ordinal data) or ANOVA (continuous data). 
Significant P-values are indicated in bold.
Aza, azathioprine; CyA, cyclosporin A; MMF, mycophenolate mofetil; Tac, tacrolimus.
TABLE  1  (Continued)
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TABLE  2 Possible risk factors for the development of cutaneous squamous cell carcinoma in 626 organ transplant recipients (combined 
cohort)
N (%) Cause- specific univariate 
HR Adjusted HRaNo SCC SCC
No. of patients 536 90
Study center, n (%)
Leiden (The Netherlands) 172 (32.1) 20 (22.3) 1 1
Lyon (France) 144 (26.9) 19 (21.1) 1.4 (0.72- 2.6) 0.93 (0.49- 1.8)
London (UK) 126 (23.5) 29 (32.2) 1.8 (0.99- 3.2) 1.6 (0.88- 2.9)
Bergamo (Italy) 94 (17.5) 22 (24.4) 1.5 (0.83- 2.8) 1.7 (0.90- 3.1)
Sex, n (%)
Women 176 (32.8) 18 (20.0) 1 1
Men 360 (67.2) 72 (80.0) 1.7 (1.01-2.7) 2.0 (1.2-3.5)
Age at transplantation per 10 y
Median 51.9 54.8
IQR (25%- 75%) 41.9- 58.8 46.8- 61.8 1.8 (1.4-2.1) 2.1 (1.7-2.6)
Age at physical examination per 10 y
Median 57.8 64.5
IQR (25%- 75%) 51.2- 65.43 58.1- 67.6 1.9 (1.5-2.3) 2.1 (1.7-2.7)
Skin phototype, n (%)
Dark/olive 287 (53.6) 32 (35.6) 1 1
Medium 184 (34.4) 35 (38.9) 1.6 (0.99- 2.6) 1.9 (1.2-3.2)
Fair 64 (12.0) 23 (25.5) 3.3 (1.9-5.6) 3.9 (2.2-7.0)
Missing values (1)
Type of organ, n (%)
Kidney 434 (81.0) 74 (82.2) 1
Kidney and pancreas 59 (11.0) 4 (4.4) 0.45 (0.16- 1.2) 0.81 (0.28- 2.4)
Heart 43 (8.0) 12 (13.4) 1.8 (0.97- 3.3) 1.1 (0.53- 2.2)
Immunosuppressive therapy, n (%)
Aza in any combination 108 (20.2) 54 (60.0) 1 1
MMF in any combination 334 (62.4) 25 (27.8) 0.22 (0.13-0.38) 0.28 (0.15-0.50)
CyA or Tac without Aza or MMF 93 (17.4) 11 (12.2) 0.33 (0.17-0.64) 0.25 (0.13-0.50)
Missing values (1)
Average daily sun exposure, n (%)
1- 3 h 335 (62.5) 48 (53.3) 1 1
≥4 h 201 (37.5) 42 (46.7) 1.4 (0.90- 2.1) 1.1 (0.71- 1.7)
Sunburns before the age of 20 y, n (%)
0 243 (45.4) 41 (46.1) 1 1
1- 4 196 (36.7) 35 (39.3) 1.1 (0.68- 1.7) 0.91 (0.56- 1. 5)
≥5 96 (17.9) 13 (14.6) 0.92 (0.49- 1.7) 0.66 (0.33- 1.3)
Missing values (1) (1)
Smoking, n (%)
No 240 (44.9) 32 (36.0) 1 1
1- 19 pack- y 182 (34.1) 30 (33.7) 1.1 (0.69- 1.9) 0.94 (0.56- 1.6)
≥20 pack- y 112 (21.0) 27 (30.3) 1.9 (1.1-3.2) 1.1 (0.65- 1.9)
Missing values (2) (1)
(Continues)
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majority (>80%) of both cohorts were kidney transplant recipients, 
we had insufficient statistical power to assess differences in risk of 
cSCC according to type of organ transplant received. As we have re-
ported earlier,3 the number of keratotic skin lesions and common viral 
warts was strongly associated with the development of cSCC, with an 
adjusted HR of 4.7 (95% confidence interval [CI] 2.0- 10.9) for OTRs 
with 50 or more lesions compared with those OTRs with fewer lesions. 
After adjustment, sun exposure, painful sunburns, and smoking were 
not associated with cSCC in the combined cohort (Table 2).
The number of βPV types in eyebrow hair, βPV DNA load, and 
serologic responses to HPV did not significantly differ between the 
2 cohorts (Table 1). Figure 1 shows a higher overall cumulative inci-
dence of cSCC in OTRs infected with multiple (≥5) HPV types mea-
sured 12 months posttransplantation in cohort 1 and after a median 
of 10 years posttransplantation in cohort 2 compared with OTR with 
fewer βPV types or noninfected OTRs (Figure 1A). The cumulative inci-
dence of cSCC for the separate cohorts is provided in Figures S3A and 
S3B. Table 3 reports the association between presence of βPV DNA 
in eyebrow hair and subsequent development of cSCC. The combined 
adjusted HR was 1.7 (95% CI 1.1- 2.6). More detailed information is 
provided in the Tables S3- S5.
High βPV load was also associated with a significantly higher cu-
mulative incidence of cSCC compared with a low load or absent βPV 
types (Figure 1B and Table 3). In the combined cohort, the adjusted 
HR was 1.8 (95% CI 1.2- 2.8). The βPV load risk factor in cohort 1 was 
probably driving the HRs in the combined analyses.
HPV seropositivity at the time of sampling was not associated with 
cSCC risk (Figures 1C and 1D and Table 3). The association was stronger 
but still not significant for concordant serologic responses (Figure 1D 
and Table 3). We observed a weak association between γPV seroposi-
tivity and cSCC (Table 3) but no association with αPV, μPV, and νPV se-
ropositivity (Tables S3- S5). We examined possible heterogeneity of βPV 
effects between cohorts 1 and 2, but this was not the case in the univar-
iate and adjusted analyses for any of the variables in Table 3. We were 
unable to assess the influence of type of organ transplanted because 
our study populations were mostly kidney transplant recipients. There 
was no evidence of violation of the proportional hazard assumption.
Data on individual HPV types suggested that βPV of species 1, 
specifically HPV types 5, 8, 20, 21, and 36, are those most likely to be 
involved in cutaneous squamous carcinogenesis, with possible roles 
for HPV76 (species 3) and HPV92 (species 4) (Table S6). The increased 
risk of skin cancer was specific for cSCC; there were no statistically 
significant associations between HPV infection and the development 
of BCC (Table S7).
4  | DISCUSSION
In this observational hospital- based study of 2 OTR cohorts with a fol-
low- up period after HPV sampling of longer than 10 years, we found 
that the diversity and load of infecting βPV types were associated with 
an approximately doubled risk of cSCC. Our results were robust after 
adjustment for multiple potential confounders. This level of increased 
risk is equivalent to that associated with other well- established risk 
factors such as skin phototype3 and points to an important role for the 
skin virome and specifically HPV in the pathogenesis of cSCC.
HPV constitute an important part of the normal human skin vi-
rome.6,7,19,20 There is strong evidence from laboratory studies to suggest 
N (%) Cause- specific univariate 
HR Adjusted HRaNo SCC SCC
Alcohol consumption, n (%)
No 190 (41.0) 20 (23.5) 1 1
1- 19 g/d 207 (44.7) 45 (52.9) 1.6 (0.97- 2.8) 1.4 (0.83- 2.5)
≥20 g/d 66 (14.3) 20 (23.6) 2.5 (1.3-4.6) 1.8 (0.93- 3.5)
Missing values (73) (5)
Keratotic skin lesions, n (%)
0 299 (55.9) 17 (18.9) 1 1
1- 49 213 (39.8) 60 (66.7) 4.1 (2.3-7.1) 3.1 (1.7-5. 5)
≥50 23 (4.3) 13 (14.4) 8.0 (3.8-16.6) 4.7 (2.0-10.9)
Missing values (1)
Common viral warts, n (%)
0 387 (72.5) 50 (55.6) 1 1
1- 49 113 (21.1) 23 (25.6) 1.3 (0.80- 2.2) 1.3 (0.77- 2.2)
≥50 34 (6.4) 17 (18.8) 2.3 (1.3-4.1) 2.5 (1.3-5.0)
Missing values (2)
All hazard ratios (HRs) are calculated using delayed entry and adjusting for competitive risk of death. Significant HRs are indicated in bold.
Aza, azathioprine; CyA, cyclosporin A; MMF, mycophenolate mofetil; SCC, squamous cell carcinoma; Tac, tacrolimus.
aThe adjusted HRs are calculated with the factor of interest and sex, age at physical examination, skin type, and study center included in the model.
TABLE  2  (Continued)
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F IGURE  1 Cumulative incidence of cutaneous squamous cell carcinoma in organ- transplant recipients with 5 and more HPV types in 
eyebrow hair measured 12 mo post- transplant in cohort 1 and after a median of 10 years post- transplant in cohort 2 (red line) compared with 
transplant recipients with 0- 4 HPV types (black line) (Panel A); with a high βPV load in plucked eyebrow hair (red line) compared with transplant 
recipients with a low load or absence of these 8 specific βPV types (black line) (Panel B); with a positive serologic response to βPV (red line) 
compared with transplant recipients without a positive response (black line) (Panel C); with a positive serologic response to βPV in combination 
with the same βPV type(s) in the eyebrow hair (green line), and with a positive serologic response to βPV in combination with different βPV types 
in the eyebrow hair (red line) compared with transplant recipients without a positive response (black line) (Panel D). The curves are adjusted for 
competitive risk of death and for delayed inclusion of the patients. Due to the delayed inclusion, the numbers of patients at risk initially increase 
with time before they decrease [Color figure can be viewed at wileyonlinelibrary.com]
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that HPV plays a role in cSCC carcinogenesis, principally through syn-
ergy with UVR.13-15 In normal cells, UVR upregulates cellular defense 
processes leading to p53 activation, cell cycle arrest, apoptosis, or DNA 
repair. Several βPV types (eg, HPV5, HPV8, HPV38, and HPV49) de-
regulate these crucial cellular regulatory pathways by targeting multi-
ple transcription factors and/or transcriptional regulators, resulting in 
infected cells that are highly susceptible to chromosomal instability 
and malignant transformation by UVR.9,15,43 Synergy between βPV and 
UVR has also been documented in animal models. In transgenic mice 
expressing the HPV8 early region or E6 gene alone, a single dose of 
UVR rapidly promoted papillomas and cSCC formation,16 and in HPV38 
E6/E7 transgenic mice, UVR also induced the development of actinic 
keratoses and cSCC.17 Certain βPV types also appear to have enhanced 
replication in the context of host immunosuppression, likely accompa-
nied by increased oncogene expression and oncogenic activity.44
Previous epidemiologic studies investigating the association between 
βPV and cutaneous squamous carcinogenesis have generated inconsis-
tent findings.9,11,12 One of the challenges is the diversity of recognized 
HPV types within the normal skin virome.33,34 More than 200 HPV types 
have been identified, and the number of putative new types is increas-
ing.33,34,45 We tested for only a subset of HPV types. Our polymerase 
chain reaction–based βPV DNA detection technique was state- of- the- 
art when we initiated this study and remains a reliable and reproducible 
method. It is possible, however, that the true association between βPV 
infection and cSCC is even stronger, as we may have failed to detect 
additional relevant HPV infections. We also observed that seropositivity 
to γPV was associated with subsequent cSCC, supporting recent findings 
that γPV type HPV197 is commonly present in skin tumors34 and that its 
E6 and E7 proteins interact with a set of cellular proteins similar to those 
encoded by genital HPVs linked to human carcinogenesis.45
Another limitation of this study was the lack of follow- up data in 
Berlin and Verona. While this decreased the power of the study, we 
believe that it is unlikely to have introduced bias because all patients in 
these 2 centers were excluded, independent of their medical history. 
Although cohort 1 was ideally designed for analysis of the involvement 
of HPV in cSCC development, we were hampered by the low number 
of events during the first 10 years after transplantation. Therefore, 
cohorts 1 and 2 were combined, which in the crude associations 
between the presence, number, and load of βPV DNA with the later 
development of cSCC appeared similar. There were also differences 
between the 2 cohorts. In recent years, older patients were more fre-
quently transplanted, the immunosuppressive regimen changed, and a 
larger proportion of patients with a darker skin phototype were trans-
planted, especially in Leiden and London.
Other potential limitations of this study are missing data in the 
clinical characteristics included in the multivariable analyses. Of 
TABLE  3 Risk of cutaneous squamous cell carcinoma in organ transplant recipients with human papillomavirus infection according to the 
presence of βPV DNA and/or serologic response to βPV
No. of squamous cell carcinoma 
cases/total populationa
Cohort 1 
14/274
Cohort 2 
76/352
Both cohorts combined 
90/626
Risk factors
Cause- specific 
univariate HRb
Cause- specific 
univariate HR Adjusted HRc
Cause- specific 
univariate HR Adjusted HRc
βPV DNA (based on 25 βPV types)
0- 4 types 1 1 1 1 1
≥5 2.6 (0.82- 8.3) 1.8 (1.1-2.8) 1.6 (0.998- 2.7) 1.9 (1.2-2.9) 1.7 (1.1-2.6)
βPV load (based on 8 βPV types)
Low load (1 copy per ≥20 cells) 1 1 1 1 1
High load (1 copy per <20 cells) 4.6 (1.5-13.8) 1.8 (1.1-2.8) 1.5 (0.92- 2.4) 2.1 (1.4-3.1) 1.8 (1.2-2.8)
βPV serology (based on 16 βPV types)
Seronegative 1 1 1 1 1
Seropositive 1.0 (0.36- 2.9) 1.6 (1.02-2.6) 1.5 (0.90- 2.4) 1.5 (0.97- 2.3) 1.4 (0.90- 2.1)
Combination βPV DNA and serology
Seronegative irrespective DNA 1 1 1 1 1
Seropositive without concordant 
DNA
0.98 (0.25- 3.9) 1.2 (0.69- 2.2) 1.2 (0.66- 2.2) 1.2 (0.69- 2.0) 1.2 (0.71- 2.1)
Seropositive with concordant DNA 1.1 (0.31- 3.6) 2.0 (1.2-3.3) 1.7 (1.002-3.0) 1.8 (1.1-2.9) 1.5 (0.93- 2.5)
γPV serology (based on 6 γPV types)
Seronegative 1 1 1 1 1
Seropositive 1.1 (0.38- 3.1) 1.5 (0.93- 2.3) 1.7 (1.1-2.8) 1.4 (0.91- 2.1) 1.6 (1.01-2.4)
All hazard ratios (HRs) are calculated using delayed entry and adjusting for competitive risk of death. Significant HRs are indicated in bold.
aThe detailed numbers of squamous cell carcinoma per cohort and per exposure are provided in the supplementary material (Tables S3- S5).
bAdjusted HRs are not available for cohort 1 because of low number of events.
cThe HRs are adjusted for sex, age at physical examination, skin type, and study center.
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particular concern is the 28% missing data for alcohol consumption, 
but we found no evidence that adjusting for alcohol in those with com-
plete information made any difference to the estimates of association 
between HPV and cSCC. We have no good explanation why we did 
not find a statistically significant association with βPV serology. We 
have shown a 40% increased risk of cSCC overall in seropositive OTRs 
but had to exclude a substantial number of patients because of miss-
ing data, decreasing the power of our study, which may be a possible 
explanation of our failure to show a statistically significant association 
between βPV serology and cSCC.
This cohort study provides evidence that infection with βPV is 
associated with the development of cSCC. βPV vaccines are now in 
development, and our data provide a rationale for routine pretrans-
plantation screening of the skin virome for βPV content and βPV 
vaccination of high- risk individuals as a possible future strategy for 
reducing the burden of posttransplantation cSCC.
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